SBIR/STTR Research Award
FERRITE PARTICLES AS NMR IMAGING CONTRAST AGENTS
Award amount
$494,000Program and phase
SBIR · Phase IIAward year
1988Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- ADVANCED MAGNETICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
AS PART OF A COLLABORATIVE EFFORT WITH THE DEPARTMENT OF RADIOLOGY AT THE MASSACHUSETTS GENERAL HOSPITAL, ADVANCED MAGNETICS INTENDS TO ASSESS THE POTENTIAL OF LIVER-TARGETED,FERRITE-BASED CONTRAST AGENTS TO ENHANCE THE POTENTIAL OF MAGNETIC RESONANCE (MR) IMAGING FOR DETECTION OF LIVER METASTASES USING A RAT TUMOR MODEL. ALTHOUGH MOST STUDIES WITH MR CONTRAST AGENTS HAVE INVOLVED ONLY IONS OR ION- CHELATE COMPLEXES, SOME RECENT RESEARCH SUGGESTS THAT SUCH FERRITE PARTICLES CAN ACT AS POWERFUL IMAGE ENHANCEMENT CONTRAST AGENTS. ONE PROMISING TYPE OF CANDIDATE PARTICLE HAS BEEN IDENTIFIED. EFFORTS WILL BE DIRECTED TOWARD THE SYSTEMATIC SYNTHESIS OF A VARIETY OF FERRITE COMPOUNDS THAT ARE CONTROLLED FOR PARTICLE SIZE, FERRITE COMPOSITION, AND CHEMICAL COATING. THESE PARAMETERS ARE DIRECTED TOWARD PRODUCING A NON-TOXIC, PARTICULATE (COLLOIDAL) CONTRAST AGENT(S) OF CONTROLLED SIZE, SIZE DISTRIBUTION, AND CHEMICALCOATING WHOSE SURFACE PROPERTIES WILL ALLOW FOR THE EFFICIENT PHAGOCYTOSIS BY THE RETICULOENDOTHELIAL SYSTEM OF THE LIVER BUT NOT BY TUMOR NODULES. THE RESULT OF THIS SELECTIVE UPTAKE SHOULD ALLOW MAJOR IMPROVEMENTS IN THE CONTRAST BETWEEN NORMAL AND CANCEROUS TISSUES. NEW MR CONTRAST AGENTS WILL PROVIDE ADDITIONAL TOOLS FOR THE STUDY OF ORGAN PHYSIOLOGY AND METABOLISM AND OFFER CLINICAL ADVANTAGES THAT CAN RESULT IN INCREASED PATIENT/SAMPLE THROUGHPUT AND REDUCED COST PER EXAMINATION.
Technology keywords
Not reported